Entera Bio Ltd. Change in other assets and liabilities

Change in other assets and liabilities of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Change in other assets and liabilities growth rates and interactive chart.


Highlights and Quick Summary

  • Change in other assets and liabilities for the quarter ending June 29, 2020 was $-50 Thousand (a -91.41% decrease compared to previous quarter)
  • Year-over-year quarterly Change in other assets and liabilities decreased by -107.24%
  • Annual Change in other assets and liabilities for 2019 was $383 Thousand (a 11.99% increase from previous year)
  • Annual Change in other assets and liabilities for 2018 was $342 Thousand (a -6.56% decrease from previous year)
  • Twelve month Change in other assets and liabilities ending June 29, 2020 was $242 Thousand (a -7.98% decrease compared to previous quarter)
  • Twelve month trailing Change in other assets and liabilities decreased by -62.88% year-over-year
Trailing Change in other assets and liabilities for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$242 Thousand $263 Thousand $383 Thousand $652 Thousand
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Change in other assets and liabilities of Entera Bio Ltd.

Most recent Change in other assets and liabilitiesof ENTX including historical data for past 10 years.

Interactive Chart of Change in other assets and liabilities of Entera Bio Ltd.

Entera Bio Ltd. Change in other assets and liabilities for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-0.05 $-0.58
2019 $0.18 $0.69 $-0.03 $-0.46 $0.38
2018 $0.45 $-0.11 $-0.4 $0.39 $0.34
2017 $0.37

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.